Investigation on pharmacokinetics, tissue distribution and excretion of a novel anticancer platinum compound by inductively coupled plasma mass spectrometry after intravenous administration to rats

Archives of Pharmacal Research

Volumn 32, Issue 11, 2009, Pages 1621-1628

  Liu, Qing Fei ^a   Li, Xue ^a   Su, Qiang ^a,b   Luo, Guo An ^a   Wang, Yi Ming ^a   Liu, Wei Ping ^c  

^a Tsinghua University   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c KUNMING INSTITUTE OF PRECIOUS METALS   (China)

Author keywords

Excretion; ICP MS; Novel antitumor platinum compound; Pharmacokinetics; SM54111; Tissue distribution

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; SALIPLATIN; SM 54111; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATOMIC EMISSION SPECTROMETRY; BRAIN; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HEART; KIDNEY; LIVER; LUNG; MALE; NONHUMAN; OVARY; RAT; SPLEEN; TESTIS; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; MODELS, BIOLOGICAL; ORGANOPLATINUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 72049090620     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-009-2116-y     Document Type: Article

References (31)

1. D. S. Alberts P. T. Fanta K. L. Running 1997 In vitro phase II comparision of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers Cancer Chemother. Pharmacol. 39 493 497 10.1007/s002800050604 1:CAS:528:DyaK2sXis1ajtrs%3D 9118460 (Pubitemid 27096764)
2. P. Apostoli 2002 Element in environmental and occupational medicine J. Chromatogr. B 778 63 97 10.1016/S0378-4347(01)00442-X 1:CAS:528: DC%2BD38XovF2nsbs%3D
3. J. L. Carr M. D. Tingle M. J. Mckeage 2006 Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro Cancer Chemother. Pharmacol. 57 483 490 10.1007/s00280-005-0069-5 1:CAS:528:DC%2BD28XjtVyhtw%3D%3D 16172904 (Pubitemid 43087591)
4. M. J. Cleare J. D. Hoeschle 1973 Studies on the antitumor activity of Group VIII transition metal complexes. Part 1. Platinum II complexes Bioinorg. Chem. 7 187 195 10.1016/S0006-3061(00)80249-5
5. B. Desoize C. Madoulet 2002 Particular aspects of platinum compounds used at present in cancer treatment Crit. Rev. Oncol. Hematol. 42 317 325 10.1016/S1040-8428(01)00219-0 12050023 (Pubitemid 34615692)
6. T. Draqovich D. Mendelson A. Hoos J. Lewis S. Kurtin 2003 A phase II trial of aroplatln (L-NDDP), a liposomal DACH - a preliminary report Colorectal Cancer 22 582
7. H. Ehrsson I. Wallin 2003 Liquid chromatographic determination of oxaliplatin in blood using post-column derivatization in a microwave field followed by photometric detection J. Chromatogr. B 795 291 294 10.1016/S1570-0232(03)00590-7 1:CAS:528:DC%2BD3sXns1KltLs%3D (Pubitemid 37186798)
8. J. Goodisman D. Hagrman K. A. Tack A. K. Souid 2005 Analysis of cytotoxicities of platinum compounds Cancer Chemother. Pharmacol. 39 1 10
9. R. S. Go A. A. Adjei 1999 Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin J. Clin. Oncol. 17 409 422 1:CAS:528:DyaK1MXltVyrug%3D%3D 10458260
10. M. A. Graham G. F. Lockwood D. Greenslade S. Brienza M. Bayssas E. Gamelin 2000 Clinical pharmacokinetics of oxaliplatin: a critical review Clin. Cancer Res. 6 1205 1218 1:CAS:528:DC%2BD3cXjtVOqsbk%3D 10778943
11. S. Hann Z. Stefanka K. Lenz G. Stingeder 2005 Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC-ICP-MS Anal. Bioanal. Chem. 381 405 412 10.1007/s00216-004-2839-z 1:CAS:528: DC%2BD2MXht1KrtLw%3D 15455190 (Pubitemid 40253561)
12. Y. P. Ho S. C. F. Au-Yeung K. K. W. To 2003 Platinumbased anticancer agents: Innovative design strategies and biological perspectives Med. Res. Rev. 23 633 655 10.1002/med.10038 1:CAS:528:DC%2BD3sXnsFCgsb0%3D 12789689 (Pubitemid 37038095)
13. Z. Huang A. R. Timerbaev B. K. Keppler 2006 Determination of cisplatin and its hydrolytic metabolite in human serum by capillary electrophoresis techniques J. Chromatogr. A 106 75 79 10.1016/j.chroma.2005.09.042 (Pubitemid 43145836)
14. Y. Jin J. Li L. F. Rong X. W. Lv Y. Huang S. Y. Xu 2005 Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice Acta Pharmacol. Sin. 26 250 256 10.1111/j.1745-7254.2005. 00530.x 1:CAS:528:DC%2BD2MXhsVajtr0%3D 15663907 (Pubitemid 40203974)
15. M. Y. Khuhawar G. M. Arain 2005 Liquid chromatographic determination of cis-platin as platinum(II) in pharmaceutical preparation, serum and urine samples of cancer patients Talanta 66 34 39 10.1016/j.talanta.2004.09.015 1:CAS:528:DC%2BD2MXjtlKgs70%3D 18969958 (Pubitemid 40429383)
16. F. Lvi G. Metzger C. Massari G. Milano 2000 Oxaliplatin pharmacokinetics and chronopharmacological aspects Clin. Pharmacokinet. 38 1 21 10.2165/00003088-200038010-00001
17. F. R. Luo S. D. Wyrick S. G. Chaney 1999 Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats Cancer Chemother. Pharmacol. 44 19 28 10.1007/s002800050940 1:CAS:528:DyaK1MXjtlWkuro%3D 10367745 (Pubitemid 29246321)
18. B. Meibohm K. Derndoef 2002 Pharmacokinetic/pharmacodynamic studies in drug product development J. Pharm. Sci. 19 18 31 10.1002/jps.1167 (Pubitemid 34074464)
19. J. G. Morrison P. White S. McDougall J. W. Firth S. G. Woolfrey M. A. Graham 2000 Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin J. Pharm. Biomed. Anal. 24 1 10 10.1016/S0731-7085(00)00377-0 1:CAS:528:DC%2BD3cXovFaqt7c%3D 11108533 (Pubitemid 30764937)
20. P. J. O'Dwyer J. P. Stevenson S. W. Johnson 2000 Clinical pharmacokinetics and administration of established platinum drugs Drugs 59 19 27 10.2165/00003495-200059004-00003 10864227
21. T. Saito Y. Manabe H. Saito 1995 Ototoxicity of the new platinum anticancer agent TRK-710 in comparison with cisplatin ORL J. Otorhinolaryngol. Relat. Spec. 57 235 255
22. Y. Sasaki T. Amano M. Morita 1991 Phase I study and pharmacological analysis of cis-diammine (glycolato) platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion Cancer Res. 51 1472 1477 1:STN:280:DyaK3M7ksFyqtQ%3D%3D 1997185
23. Y. Sasaki T. Tamura K. Eguchi T. Shinkai Y. Fujiwara M. Fukuda Y. Ohe M. Bungo N. Horiuchi S. Niimi K. Minato K. Nakagawa N. Saijo 1989 Pharmacokinetics of (glycolato-O,O diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin Cancer Chemother. Pharmacol. 23 243 246 10.1007/BF00451649 1:STN:280:DyaL1M7mvVGqtA%3D%3D 2647312 (Pubitemid 19093746)
24. Q. Su Q. F. Liu Q. L. Liang Y. M. Wang K. S. Bi W. P. Liu G. A. Luo 2007 Application of HPLC-ESI-MS/MS to the determination of a novel antitumor platinum complex Chem. J. Chin. Univ. 28 1486 1488 1:CAS:528:DC%2BD2sXpvVSnsb8%3D
25. Q. Su Q. F. Liu G. A. Luo W. P. Liu Y. Yu Y. M. Wang K. S. Bi 2008 Pharmacokinetic investigation on a novel antitumor platinum compound in rabbit plasma by inductively coupled plasma mass spectrometry after intravenous administration Drug Devel. Indus. Pharm. 34 472 477 10.1080/03639040701662560 1:CAS:528:DC%2BD1cXmvFWrs70%3D (Pubitemid 351878690)
26. Q. Su Q. F. Liu J. F. Wu G. A. Luo Y. M. Wang K. S. Bi W. P. Liu 2007 Application of high performance capillary electrophoresis tandem mass spectrometry to the investigation on the stability of novel anticancer platinum complex in solution Chin. J. Anal. Chem. 35 1721 1725 1:CAS:528: DC%2BD1cXhslSqsL0%3D
27. Q. Su Q. F. Liu Y. Yu Y. M. Wang K. S. Bi W. P. Liu G. A. Luo 2007 Assay of platinum coordination by high performance liquid chromatography Chin. J. New Drug 16 791 793 1:CAS:528:DC%2BD2sXms12itLs%3D
28. K. Suzuki Y. Moritani N. Hisamichi 2002 Pharmacodynamics and pharmacokinetics of YM128, a GPIIb/IIIa antagonist prodrug Drug Dev. Res. 55 146 161 10.1002/ddr.10047 (Pubitemid 34602875)
29. J. Welink B. Pechstein W. J. F. Vigh 1999 Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection J. Chromatogr. B 675 107 111
30. E. Wong C. M. Giandomenico 1999 Current Status of Platinum-Based Antitumor Drugs Chem. Rev. 99 2451 2466 10.1021/cr980420v 1:CAS:528: DyaK1MXltFSrsrc%3D 11749486
31. Yu, Y., Study of a novel antitumour Platinum compoun, Dissertation. Kunming Institute of Precious Metal (2006).